Stock MSSV MESO NUMISMATICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Meso Numismatics, Inc.

Equities

MSSV

US59071L1035

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 03:40:26 2024-05-16 pm EDT 		5-day change 1st Jan Change
0.036 USD -3.81% Intraday chart for Meso Numismatics, Inc. 0.00% +393.15%
Apr. 15 Meso Numismatics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 04 Meso Numismatics, Inc. will Change its Name to Regenerative Medical Technology Group Inc CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 0.2392 0.1423 0.2935 3.249 0.2364 0.0912
Enterprise Value (EV) 1 1.021 1.726 6.03 13.64 13.73 17.21
P/E ratio -0.1 x -0.04 x -0.05 x -0.24 x -0.04 x -0.01 x
Yield - - - - - -
Capitalization / Revenue 4.77 x 4.73 x 5.33 x 6.84 x 0.15 x 0.04 x
EV / Revenue 20.4 x 57.3 x 109 x 28.7 x 8.97 x 7.14 x
EV / EBITDA -4.27 x -1.1 x -13.9 x -1.39 x -16.3 x -43.5 x
EV / FCF 0.66 x 1.64 x -1.04 x -2.87 x 24.1 x 29 x
FCF Yield 151% 61.1% -96.3% -34.8% 4.14% 3.45%
Price to Book -0.05 x -0.02 x -0.05 x -0.48 x -0.02 x -0 x
Nbr of stocks (in thousands) 4,901 7,245 9,173 12,032 12,444 12,494
Reference price 2 0.0488 0.0196 0.0320 0.2700 0.0190 0.007300
Announcement Date 4/17/19 12/9/20 4/13/21 5/5/22 4/14/23 4/15/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.0501 0.0301 0.0551 0.4753 1.53 2.41
EBITDA 1 -0.2391 -1.569 -0.4352 -9.791 -0.8417 -0.3961
EBIT 1 -0.2393 -1.57 -0.436 -9.832 -0.9945 -0.7062
Operating Margin -477.41% -5,213.91% -791.53% -2,068.81% -64.99% -29.3%
Earnings before Tax (EBT) 1 -2.058 -2.509 -5.896 -12.88 -5.575 -9.814
Net income 1 -2.058 -2.509 -5.896 -12.88 -5.507 -9.814
Net margin -4,105.61% -8,335.2% -10,703.47% -2,711.03% -359.87% -407.21%
EPS 2 -0.5032 -0.4729 -0.6311 -1.122 -0.4507 -0.7900
Free Cash Flow 1 1.537 1.055 -5.806 -4.749 0.5689 0.5941
FCF margin 3,067.06% 3,506.04% -10,540.5% -999.22% 37.18% 24.65%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/17/19 12/9/20 4/13/21 5/5/22 4/14/23 4/15/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 0.78 1.58 5.74 10.4 13.5 17.1
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -3.271 x -1.01 x -13.18 x -1.062 x -16.03 x -43.22 x
Free Cash Flow 1 1.54 1.06 -5.81 -4.75 0.57 0.59
ROE (net income / shareholders' equity) 58% 42.5% 86.7% 197% 59.5% 58.1%
ROA (Net income/ Total Assets) -704% -3,216% -221% -129% -7.15% -8.06%
Assets 1 0.2923 0.078 2.662 9.986 77.02 121.8
Book Value Per Share 2 -0.9300 -0.9200 -0.5900 -0.5600 -0.9600 -1.740
Cash Flow per Share 2 0.0100 0 0 0.2500 0.1300 0.0400
Capex 1 0 - - - 0.2 0.39
Capex / Sales 7.98% - - - 12.97% 16%
Announcement Date 4/17/19 12/9/20 4/13/21 5/5/22 4/14/23 4/15/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MESO NUMISMATICS, INC. Stock Meso Numismatics, Inc.
+393.15% 450K
MODERNA, INC. Stock Moderna, Inc.
+33.31% 50.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.73% 42.82B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.03B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.93% 26.11B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.67% 19.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+9.09% 13.05B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.42% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+23.80% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MSSV Stock
  4. Financials Meso Numismatics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW